Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA for TRANQUILITY In-Care pivotal Phase 3 trial for agitation associated with Alzheimer's dementia Company to maintain IGALMI™ in the market without current commercial infrastructure NEW HAVEN, Conn., Sept. 19, 2024 (GLOBE NEWSWIRE) -- — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformat ...